{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:02:01Z","timestamp":1792875721575,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110734","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:05:14Z","timestamp":1761260714000},"page":"110734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The enhanced Wnt\/\u03b2-catenin pathway upregulation by sacubitril\/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model"],"prefix":"10.1016","volume":"283","author":[{"given":"Rania Tarek","family":"Elkhial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy M.","family":"Awny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsayed K.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-9002","authenticated-orcid":false,"given":"Shahira","family":"Nofal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2025.110734_bib1","doi-asserted-by":"crossref","DOI":"10.2174\/1573403X17666210831142452","article-title":"Sacubitril\/valsartan: a new dawn has begun! A revisited review","volume":"18","author":"Abdelnabi","year":"2022","journal-title":"Curr. Cardiol. Rev."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110734_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24129876","article-title":"Tannic acid mitigates rotenone-induced dopaminergic neurodegeneration by inhibiting inflammation, oxidative stress, apoptosis, and glutamate toxicity in rats","volume":"24","author":"Azimullah","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"FEB","key":"10.1016\/j.neuropharm.2025.110734_bib3","article-title":"Atrial natriuretic peptide acts as a neuroprotective agent in in vitro models of Parkinson's disease via up-regulation of the Wnt\/\u03b2-catenin pathway","volume":"10","author":"Baldeschi","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110734_bib4","series-title":"Theory and Practice of Histological Techniques","first-page":"1","author":"Bancroft","year":"2007"},{"key":"10.1016\/j.neuropharm.2025.110734_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2014.09.068","article-title":"Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats","volume":"1593","author":"Bassani","year":"2014","journal-title":"Brain Res."},{"issue":"s1","key":"10.1016\/j.neuropharm.2025.110734_bib6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"Jan","key":"10.1016\/j.neuropharm.2025.110734_bib7","article-title":"Study of the possible effect of sacubitril\/valsartan combination versus valsartan on the cognitive function in Alzheimer's disease model in rats","volume":"37","author":"El-din Hussein","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110734_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jbt.21821","article-title":"Ameliorative effect of quercetin on neurochemical and behavioral deficits in rotenone rat model of Parkinson's disease: Modulating autophagy (quercetin on experimental Parkinson's disease)","volume":"30","author":"El-Horany","year":"2016","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.neuropharm.2025.110734_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neuro.2019.03.005","article-title":"Neuroprotective role of kolaviron in striatal redo-inflammation associated with rotenone model of Parkinson's disease","volume":"73","author":"Farombi","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2025.110734_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12017-019-08590-2","article-title":"Naringin exhibits neuroprotection against rotenone-induced neurotoxicity in experimental rodents","volume":"22","author":"Garabadu","year":"2017","journal-title":"NeuroMolecular Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110734_bib11","first-page":"1","article-title":"Natriuretic peptides are neuroprotective on in vitro models of PD and promote dopaminergic differentiation of hiPSCs-derived neurons via the Wnt\/\u03b2-catenin signaling","volume":"7","author":"Giovannini","year":"2021","journal-title":"Cell Death Discovery 2021"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110734_bib12","first-page":"1","article-title":"Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach","volume":"3","author":"Iborra-Egea","year":"2017","journal-title":"npj Systems Biol. Appl."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110734_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/alz.12926","article-title":"Circulating cardiac biomarkers, structural brain changes, and dementia: emerging insights and perspectives","volume":"19","author":"Jensen","year":"2023","journal-title":"Alzheimer's Dement."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110734_bib14","first-page":"4683","article-title":"Quercetin improves blood-brain barrier dysfunction in rats with cerebral ischemia reperfusion via Wnt signaling pathway","volume":"11","author":"Jin","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.neuropharm.2025.110734_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.615131","article-title":"Inflammation and wnt signaling: target for immunomodulatory therapy?","volume":"8","author":"Jridi","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2025.110734_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/bs.ant.2019.11.004","article-title":"Rotenone neurotoxicity: relevance to Parkinson's disease","volume":"4","author":"Lawana","year":"2020","journal-title":"Adv Neurotoxicol."},{"key":"10.1016\/j.neuropharm.2025.110734_bib17","series-title":"\u201cCrosstalk Between wnt\/\u03b2-catenin and NF-\u03baB Signaling Pathway During Inflammation,\u201d","author":"Ma","year":"2016"},{"key":"10.1016\/j.neuropharm.2025.110734_bib18","series-title":"Wnt\/\u03b2-catenin Signaling pathway-a Versatile Player in Apoptosis and Autophagy","author":"Ma","year":"2023"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110734_bib19","first-page":"943","article-title":"Assessment of gait dynamics in rotenone-induced rat model of Parkinson's disease by footprint method","volume":"30","author":"Madiha","year":"2017","journal-title":"Article Pakistan J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2025.110734_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.967813","article-title":"Neuroprotective and therapeutic effects of calcitriol in rotenone-induced Parkinson's disease rat model","volume":"16","author":"Magdy","year":"2022","journal-title":"Front. Cell. Neurosci."},{"issue":"NOV","key":"10.1016\/j.neuropharm.2025.110734_bib21","article-title":"Natriuretic peptides in post-mortem brain tissue and cerebrospinal fluid of non-demented humans and Alzheimer's disease patients","volume":"12","author":"Mahinrad","year":"2018","journal-title":"Front. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110734_bib22","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.3390\/ijms19123743","article-title":"Wnt\/\u03b2-Catenin signaling pathway governs a full program for Dopaminergic neuron survival, neurorescue and regeneration in the MPTP mouse model of Parkinson's disease","volume":"19","author":"Marchetti","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110734_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13101","article-title":"Parkinson's disease, aging and adult neurogenesis: Wnt\/\u03b2-Catenin signalling as the key to unlock the mystery of endogenous brain repair","volume":"19","author":"Marchetti","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.neuropharm.2025.110734_bib24","unstructured":"D. M. Monir, O. G. Ahmed, M. E. Mahmoud, and A. A. A. Hamid, \u201cBehavioral Evaluation of Rotenone Model of Parkinson's Disease in Male Wistar Rats.\u201d."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110734_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12993-020-00171-9","article-title":"Forced exercise activates the NrF2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats","volume":"16","author":"Monir","year":"2020","journal-title":"Behav. Brain Funct."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110734_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21608\/smj.2020.21596.1089","article-title":"Behavioral evaluation of rotenone model of Parkinson's disease in Male Wistar rats","volume":"24","author":"monir hegab","year":"2020","journal-title":"Sohag Med. J."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110734_bib27","first-page":"5","article-title":"Sacubitril-Valsartan","volume":"38","author":"Nicolas","year":"2024","journal-title":"Pharma-Kritik"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110734_bib28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00210-018-1474-8","article-title":"Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson's disease","volume":"391","author":"Palle","year":"2018","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuropharm.2025.110734_bib29","article-title":"Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson's disease","volume":"112","author":"Rengasamy","year":"2020","journal-title":"Article J. Chem. Neuroanatomy"},{"issue":"JUNE","key":"10.1016\/j.neuropharm.2025.110734_bib30","article-title":"WNT signalling in neuronal maturation and synaptogenesis","volume":"7","author":"Rosso","year":"2013","journal-title":"Front. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110734_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/1673-5374.343908","article-title":"The Wnt\/\u03b2-catenin signaling: a multifunctional target for neuroprotective and regenerative strategies in Parkinson's disease","volume":"18","author":"Serafino","year":"2023","journal-title":"Neural Regen. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110734_bib32","first-page":"441","article-title":"MiRNA-384-5p regulates the progression of Parkinson's disease by targeting SIRT1 in mice and SH-SY5Y cells","volume":"45","author":"Tao","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110734_bib33","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/brainsci14060596","article-title":"Neuroprotective potentials of berberine in rotenone-induced Parkinson's disease-like motor symptoms in rats","volume":"14","author":"Tseng","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2025.110734_bib34","series-title":"Cannabidiol and the Canonical wnt\/\u03b2\u2010catenin Pathway in Glaucoma","author":"Vall\u00e9e","year":"2021"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110734_bib35","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1159\/000484302","article-title":"Protective effect of curcumin against oxidative stress-induced injury in rats with parkinson's disease through the Wnt\/\u03b2-Catenin signaling pathway","volume":"43","author":"Wang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110734_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/aps.2017.49","article-title":"Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2025.110734_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2020.02.009","article-title":"Drp1, a potential therapeutic target for Parkinson's disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model","volume":"325","author":"Zhang","year":"2020","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.neuropharm.2025.110734_bib38","series-title":"\u201cWnt\/TLR Dialog in Neuroinflammation, Relevance in Alzheimer's Disease,\u201d","author":"Zolezzi","year":"2017"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110734_bib39","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/antiox12051134","article-title":"JAC4 alleviates rotenone-induced parkinson's disease through the inactivation of the NLRP3 signal pathway","volume":"12","author":"Zou","year":"2023","journal-title":"Antioxidants"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:24:48Z","timestamp":1780820688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S0028390825004423"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110734","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The enhanced Wnt\/\u03b2-catenin pathway upregulation by sacubitril\/valsartan via neprilysin inhibition compared to valsartan in the rotenone induced Parkinson's disease rat model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110734"}}